Irinotecan Hydrochloride Injection
Product Images NDC 72485-213

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 72485-213). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (7248521315)

This is a drug called Irinotecan Hydrochloride, supplied as a sterile aqueous solution in a single-dose vial. Each mL of the solution contains 20mg of the active ingredient, Irinotecan Hydrochloride (as trihydrate) with sorbitol powder, lactic acid, and water for injection as other components. The drug is intended for intravenous use only and is labeled as a cytotoxic agent. The drug package contains important information on dosage, storage, and disposal, including the need to discard any unused portion. The drug is manufactured by Armas Pharmaceuticals in the US and distributed by Shilpa Medicare Limited in India.*

FDA Label Image

Image Description (Fig3)

This is a Figure 3 which displays the probability of survival of patients who received second-line Irinotecan treatment compared to best supportive care (BSC) in Study 7. The data includes the number of patients (N) which was 189, the median follow-up which was 13 months, and the median survival time in months which was 92 for Irinotecan and 65 for BSC. It also indicates the use of a log-rank test.*

FDA Label Image

Image Description (Fig4)

FDA Label Image

Image Description (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.